Digital health tools can capture gait frequently and remotely in people with multiple sclerosis, but interpreting longitudinal changes has been hampered by a lack of established thresholds. In a recent preprint, Rinderknecht and colleagues set out to define minimal clinically important differences (MCIDs) for smartphone-derived gait measures, using data from the phase 3b CONSONANCE study of ocrelizumab in progressive MS.

The study included 243 patients with progressive MS who performed daily remote Two-Minute Walk Tests via smartphone. The authors used an anchor-based approach, computing median changes from baseline to Week 96 for patients who showed clinically meaningful worsening on any of four anchors: Timed 25-Foot Walk, Ambulation Score, Expanded Disability Status Scale, or the 12-item Multiple Sclerosis Walking Scale. They then triangulated these changes across anchors to derive MCID estimates.

The resulting MCIDs were: step velocity -0.16 m/s, step velocity scaled to walking time -0.18 m/s, step duration 0.06 s, step length -0.07 m, total number of steps -28, and total distance walked -24 m. Median changes were generally consistent across the four anchors, supporting the robustness of the estimates.

The authors argue that these thresholds provide a framework for interpreting meaningful gait changes, potentially enabling novel clinical trial endpoints and more objective, real-world monitoring for personalized care. As a preprint, the work has not yet undergone peer review, but it addresses a clear gap in the use of digital measures for MS outcome evaluation.